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Abstract
Laboratory diagnostics play an important role in the treat-
ment of patients with acute poisoning. The classical clinical
chemistry and hematology tests help initiate supportive treat-
ment, and specialized methods enable elucidation of the poi-
sons involved. In this context, two different analytical
approaches are used: the direct quantification of a potentially
involved compound or screening procedures looking either
for a distinct drug class or a wide variety of different com-
pounds. The most common tests are immunoassays, which
have the advantage of being fast and highly automated.
These assays are available for the substances which are often
involved in intoxications. The other analytical technique
which is widely used is hyphenated chromatography con-
sisting of either high-performance liquid chromatography or
gas chromatography as chromatographic systems and detec-
tion with a diode-array or mass spectrometer. Whereas gas
chromatography mass spectrometry screening procedures
have been known for a long time, liquid chromatography
mass spectrometry screening methods are now developed by
different research groups and still need to prove their relia-
bility. In this review, the different analytical technologies and
their application will be discussed.
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Introduction
Depending on the severity of the clinical symptoms and the
substances involved, intoxications may be very serious
events, requiring intensive supportive care and special care
adapted to the poison. Therefore, laboratory diagnostics is
needed in two different fields of activity. First, laboratory
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tests need to describe the pathophysiological state of the
patient. At a minimum, these include coagulation tests, blood
cell counts, blood gas tests, serum electrolytes, liver and kid-
ney function tests, glucose, creatine kinase and osmolality.
Except for osmolality, these are very common and fully auto-
mated tests which can usually be performed within a very
short period of time. With these test results supportive treat-
ment can be initiated.
As clinical symptoms of intoxications are usually not char-
acteristic of a specific substance, in many cases subsequent
toxicological analysis is needed unless anamnestic informa-
tion provides enough evidence. There are very different indi-
cations for identifying the compounds involved in intoxi-
cations. Reasons include application of a specific therapy
(e.g., antidote) for the poison, transfer of the patient to the
intensive care unit or forensic reasons. Depending on the
motivation for the investigation, the need for a short turn
around time may be important. There are different strategies
used and described for this purpose, depending on the meth-
ods available in the laboratory. For the most common drugs
involved in intoxications, specific immunoassays for quan-
tification in serum have long been available (e.g., acetamin-
ophen, salicylates). Fully automated immunoassays are also
available for the detection of the classic drugs of abuse.
These immunoassays can be established in every clinical
chemistry laboratory, but they can also be used in the emer-
gency stations using point-of-care test devices. This allows
these tests to be available in many clinical settings. Unfor-
tunately, it is well known that these immunoassays for drugs
of abuse have numerous technical problems, such as different
cross-reactivities of the antibodies against drug metabolites,
different compounds from the same drug class, or structur-
ally similar substances from different drug classes. The high-
dose hook effect or the commonly applied cut-off
concentrations that are well above the limits of detection of
the respective tests are other factors which have to be con-
sidered when using these tests in clinical toxicology. In addi-
tion, new amphetamine-like designer drugs have entered the
drugs of abuse scene we.g., piperazines (1)x, which cannot be
detected by immunoassays. Thus, hyphenated chromato-
graphic techniques using mass spectrometry as detection
methods are widely used in specialised toxicological labo-
ratories. Gas chromatography coupled to mass spectrometry
(GC-MS) has been the gold standard since the early 1980s,
and is still in common use today (2). In recent years, liquid
chromatography coupled with mass spectrometry (LC-MS)
has gained the interest of many researchers in clinical and
forensic toxicology. This technique can be used in a more
flexible way compared with GC-MS, and the turnaround
time is usually much shorter (3–6).
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Colorimetric tests often can be performed very rapidly by
adding a simple reagent to a patient sample, and are not
burdened with high instrumental costs. The colour which is
developed sometimes allows the identification of a single
drug we.g., phenothiazines with the Forrest test (7)x. Usually,
these tests are less specific than chromatographic or immu-
nological tests. Therefore, these tests are being replaced by
these techniques in many laboratories which can afford the
investment of immunoassay analyzers of chromatographic
methods. However, they are routinely used for the identifi-
cation of cyanide and iron in most laboratories.
Following identification of the substances involved in
intoxication, often a quantitative or, at a minimum, a semi-
quantitative measurement is needed for adequate patient
treatment. Quantifications of poisons should be performed in
serum or plasma in order to enable correlation of the drug
concentration with the degree of intoxication. Optimally,
screening procedures enable estimation of the concentration
of the poison. If this cannot be accomplished, a specific
quantitative assay needs to be performed.
In the following sections, the most important and generally
well-accepted parameters or procedures used in acute poi-
soning are reviewed, and their usefulness in different situa-
tions are discussed.
Immunoassays
Immunoassays are widely used in acute poisoning since they
are widely available in many laboratories. The rating of these
tests in acute clinical toxicology cannot be assessed in total.
Immunoassay tests for therapeutic drugs or drugs of abuse
are usually developed for a single matrix, e.g., urine or
serum/plasma. One of the major reasons to do so is that the
compound predominantly present in the particular matrix
(drug and/or drug metabolite) which is detected by the assay
is often not the same in blood and urine (8). The other impor-
tant factor is the concentration range of the detected com-
pound present in the respective matrix, which may vary
widely. However, many clinical and forensic toxicological
laboratories use the drugs of abuse tests developed for urine
to analyze blood samples. If a laboratory decides to use an
immunoassay for a matrix that it is not intended, a very
careful evaluation of the assay needs to be performed includ-
ing comparison of the results with a chromatographic meth-
od. Also, interpretation of the test results should be
performed very carefully, taking into account the above men-
tioned caveats.
Acetaminophen (paracetamol)
If the intake of acetaminophen is suspected, quantitative
determination of the drug in serum is highly recommended
since initiation of antidotal therapy is dependent on the drug
concentration. The use of a nomograph relating plasma drug
concentration, time since ingestion and hepatotoxicity is
helpful in the evaluation for the need for antidotal treatment
(9). Blood collection should be performed at least 4 h after
suspected intake of the drug. Acetaminophen is extensively
metabolized, and only 1%–4% is excreted unchanged in
urine following intake of therapeutic doses. In the case of an
overdose, the amount that is excreted unchanged may
increase to 10%–14% of the dose (10). The immunoassays
that are used determine only acetaminophen itself, and do
not show significant cross-reactivities with metabolites.
There are enzymatic tests for quantification of acetamino-
phen in serum. Unfortunately, many of these tests are influ-
enced by bilirubin and/or other compounds present in the
serum of patients with liver injury (11). Polson et al. con-
cluded that patients with acetaminophen intoxication usually
do not have increased bilirubin concentrations when they are
admitted to the hospital. In our experience, we occasionally
see patients diagnosed with acute liver failure with pre-exist-
ing chronic liver impairment as a result of chronic infection
with hepatitis viruses, and who have greatly increased bili-
rubin concentrations. Since acetaminophen is always a can-
didate for worsening of the disease, it is usually determined
in these situations. This may result in incorrect interpreta-
tions if the assay being used is influenced by bilirubin or
other compounds that are increased in chronic liver impair-
ment (12).
Digoxin
In many countries, intoxication with digoxin has become
very rare. However, the clinical symptoms may be very
severe. Since there is a specific antibody available as an anti-
dote, it is highly recommended that digoxin be measured
whenever acute poisoning is suspected. Immunoassays used
for quantification of this drug have been shown to interact
with endogenous digoxin-like immunoreactive substances
(DLIS). DLIS are increased in patients with volume expan-
sion. This includes patients with uremia, essential hyperten-
sion, liver disease and preeclampsia. In addition, exogenous
DLIS have been described with use of various Chinese med-
icines, spironolactone or canrenone (13). Digoxin is one of
the compounds which usually cannot be determined using
the general chromatographic unknown screening procedures,
and therefore always needs to be analyzed specifically with
immunoassays.
Amanitin
Amanitin is the toxin found in poisonous Amanita sp. mush-
rooms. A chromatographic method has been described to
analyze this toxin (14), but the commercial immunoassay
that is available is more widely used since it can be per-
formed faster and does not require an LC-MS instrument.
Due to the special chemical structure of amanitin, the immu-
noassay is very specific for this compound. This immuno-
assay is usually available in specialized toxicological
laboratories in geographic areas where the mushroom grows.
Because acute poisoning with Amanita sp. leads to very
severe intoxication, antidotal therapy needs to be initiated
before result from the laboratory are available. After inges-
tion of mushrooms containing amanitin, the clinical symp-
toms usually start within 16–24 h. The ability to detect
amanitin in serum or plasma is about 30 h only, whereas it
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can be detected for up to 3 days in urine (15). Therefore, the
assay should be performed using urine samples, but it is also
acceptable to use serum or plasma.
Drugs of abuse
As mentioned above, immunoassays for the classic drugs of
abuse are available in many hospital laboratories or emer-
gency stations, have a short turn around time and are there-
fore, usually the first methods applied in toxicological
screening procedures. The results need to be interpreted with
utmost care as these tests have some major disadvantages
when used in cases of acute poisoning despite their advan-
tage of being widely available and having a short turn around
time.
The primary disadvantage of the commonly used immu-
nological tests for drugs of abuse in acute clinical toxicology
is the application of an appropriate cut-off concentration for
identifying the results as being ‘‘positive’’ or ‘‘negative’’.
All tests performed with clinical chemistry instruments are
calibrated and generate quantitative results. As the urine
matrix can be very different between individuals, and the
ratio between parent drug and metabolite(s) also can vary
greatly, these results are usually considered to be semi-quan-
titative. Starting initially in the US workplace drug testing
community, cut-off concentrations have been defined which
are well above the limit of detection of the respective drug
or drug class (16). Whenever the urine concentration of a
drug is lower than the cut-off concentration, the result is
considered to be ‘‘negative’’, despite the fact that in some
cases the concentrations indicate the actual presence of this
compound in the urine sample. This plays an important role
in patients with polyuria, or in situations where the dosages
needed to have a clinical effect diverge widely (e.g., ben-
zodiazepines). I am not aware of any studies that describe
the limit of detection of drugs of abuse tests from the dif-
ferent manufacturers. If a point-of-care device is used, the
situation is even worse since the read-out for a positive result
is only developed above the cut-off concentration. Further-
more, it should be mentioned that, especially in Europe, not
all manufacturers use the same calibrator and often apply
different cut-off concentrations. This can result in very dif-
ferent results if a urine sample is analyzed by different lab-
oratories. In addition, a negative test result is usually
considered to be correct, and if confirmation testing is per-
formed, it is usually performed only for positive screening
results.
The different cross-reactivities of antibodies with the dif-
ferent drugs or drug metabolites of a class of drugs can also
lead to misinterpretation, especially in the case of negative
results. Due to the different chemical structures of the drugs
belonging to the benzodiazepines and amphetamines, screen-
ing for these two drug classes with immunoassays are usually
the most troubled with this problem (17).
Several laboratories apply these drugs of abuse tests to
serum or plasma samples (18). Due to the different concen-
trations of drugs in serum compared with urine, and the dif-
ferent patterns between drug and drug metabolites, this
practice cannot be recommended if it is not intended by the
manufacturer.
Hyphenated chromatographic methods
Hyphenated chromatographic methods, primarily GC-MS
and LC-MS, are widely used in specialized toxicological
laboratories for either dedicated quantification of one single
compound we.g., g-hydroxybutyrate (GHB)x, a class of com-
pounds (e.g., glycols), a wide range of specific compounds
(e.g., targeted screening), or in a more global way for general
screening of unknown drugs.
Quantification of a single compound using hyphenated
chromatographic methods is usually applied when the poison
is known. However, several analytes require very specific
procedure in order to be detected in patient samples (e.g.,
GHB, colchicine). As these quantitative methods have sim-
ilar properties to the classic therapeutic drug monitoring
(TDM) methods using hyphenated chromatographic meth-
ods, they will not be discussed further in this review.
General unknown screening
General unknown screening (GUS) or systematic toxicolog-
ical analysis (STA) is used to screen for unknown com-
pounds in a patient’s urine or serum. The technique used for
this purpose needs to be able to separate and detect a wide
variety of different compounds. The combination of high-
performance liquid chromatography (HPLC) with diode-
array detection (HPLC-DAD) or mass spectrometric
detection (LC-MS or LC-MS/MS), or a GC with mass spec-
trometric detection (GC-MS) are all capable of performing a
GUS procedure. To perform chromatographic separation of
the analytes, GC requires hydrolysis of the very polar con-
jugate metabolites prior to analysis (2). HPLC methods usu-
ally can handle a wider range of polar substances if a
gradient is applied to the mobile phase.
The identification of substances after chromatography
depends on two different factors. First, the substance needs
to have either UV absorption above 200 nm or must be ioni-
sable before entering the MS. With respect to ionization,
there are big differences between GC and HPLC methods,
resulting in many more compounds which can be ionized
after GC analyses as compared with HPLC. Second, the
compound to be identified needs to be part of the library
used for identification. There are commercial libraries avail-
able of DAD spectra containing approximately 3000 differ-
ent spectra of potential compounds being found in cases of
intoxication (19). For GC-MS, there are several commercial
specialized libraries available for drugs, poisons, pesticides,
pollutants and their metabolites containing )7800 spectra
(20). Also, there are large libraries containing spectra from
)200,000 chemical entities from very different fields
(NIST07 Spectral Data, Wiley Registry of Mass Spectral
Data). The commercially available libraries for HPLC-DAD
and GC-MS can be applied for use on any instrument from
any manufacturer, fulfilling the technical requirements for
screening procedures. For LC-MS, at present there is no
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commercial library available and all research groups working
on the establishment of LC-MS GUS methods need to devel-
op their own library consisting of tandem mass spectra if
using a triple-stage quadrupol or an ion trap instrument. Not
only do the different ionization techniques welectrospray
(ESI) vs. atmospheric pressure chemical ionization (APCI)x
generate different mass spectra, but instruments from differ-
ent manufacturers and from a single manufacturer with dif-
ferent construction of the mass analyzer may result in
changes in fragmentation or in fragment intensity (21). If a
time-of-flight instrument (TOF) is used, all masses reaching
the detector can be seen in the chromatogram, independent
of the presence of the corresponding mass in the library. This
allows one to determine whether any additional substances
are present in the chromatogram. TOF instruments did not
allow generation of mass spectra (22), but new instruments
combine a quadrupol with the time-of-flight technique (Q-
TOF). Therefore, these instruments allow not only the detec-
tion of the exact mass of the parent ion, but Q-TOF
instruments enable fragmentation of selected ions within the
collision cell, followed by the measurement of the accurate
mass spectrum of the fragments (23). If tandem mass spec-
trometry is used, the production of a MS/MS spectrum is
usually only induced when the mass to charge ratio of the
parent compound has been listed as a potential candidate
compound. Depending on the concentration of a compound
not envisaged for detection and identification, and the exact
method applied in the mass spectrometer, it might be that
this additional substance cannot be detected at all in the
chromatogram. This makes the LC-MS/MS screening meth-
ods to targeted screening methods with a distinct number of
compounds which can be identified (24). Dresen et al. have
recently published an ESI-MS/MS library containing 1253
compounds, which could be applied not only on the type of
instrument on which the spectra have been recorded, but also
on two other instrument types from the same manufacturer
using a linear ion trap for detection.
As the ionization process in LC-MS has limitations con-
cerning the number of molecules which can be ionized at a
given time, these methods are always at risk for ion sup-
pression. This is true for both ionization techniques, ESI and
APCI, but ESI is much more prone to ion suppression than
APCI (25). If two substances are eluted concomitantly from
the HPLC column, the substance that is ionized more easily
will be more favorably ionized. The interfering compounds
might derive from the matrix or from other exogenous com-
pounds that may be present in higher concentrations. Espe-
cially in patients with intoxication, it is unknown which
compounds are present and it could be fatal if one peak of
a toxic compound is suppressed by the presence of another
molecule. It is therefore mandatory for all LC-MS GUS pro-
cedures to carefully test for ion suppression using real patient
samples (26).
If general screening for unknown compounds is per-
formed, the information about the detected compounds is
very important. Not all the methods described above allow
detection of every substance potentially involved in intoxi-
cations. Organic solvents (e.g., ethanol, methanol or ethylen-
glycol) and metals (e.g., lithium) cannot be detected by any
of the above mentioned screening methods. The identifica-
tion of other substances is highly dependent on the extraction
method used and the analytical technique applied, as well as
the library used for the identification of the unknown com-
pound. Therefore, it is mandatory that the specialized toxi-
cological laboratory has a GUS strategy established which
consists of immunoassays, enzymatic tests and different
chromatographic protocols to allow GUS in a potentially poi-
soned patient. In rare situations, atomic absorption spectrom-
etry (AAS) or inductively coupled plasma-mass spectrometry
(ICP-MS) should be available for the identification of metals.
In Figure 1, a graph is shown representing the GUS strategy
in our laboratory. A thorough discussion of each case
between the toxicologist performing the analyses and the
physician treating the patient is mandatory.
Targeted screening
Identification and confirmation of positive drugs of abuse
screening tests in urine have long been performed using GC-
MS. In recent years, many laboratories have changed their
methods for drugs of abuse confirmation to LC-MS/MS, and
also have developed analytical methods for screening tests
for drug classes, such as antidiabetic drugs, diuretics or lax-
ative agents (27). Usually these assays use selected reaction
monitoring (SRM) observing one or more transitions. It
should be considered that the different compounds may have
one common transition resulting in interference, as recently
shown by Sauvage et al. (28). These targeted screening pro-
cedures are usually applied when there is some evidence that
the respective drug class is involved in cases of intoxication.
Quantification of the poison
As the concentration of the poison often helps in deciding
on treatment of the patient an estimation of the identified
compound(s) is often needed. If urine is used as sample
material for screening, estimation of the concentration of the
poison in urine gives only a rough estimate about the ingest-
ed amount of the drug. If serum or plasma is used for screen-
ing purposes, direct quantification can be performed (29).
The analytical method for quantification needs to be fully
validated in order to ensure correct results. As it is not pos-
sible to have fully validated quantitative methods for all
possible poisons available, in many cases a semi-quantitative
estimation of the concentration based, for example, on a one-
point calibration or on the standard addition method can be
helpful.
As the absorption of a given compound at a distinct wave-
length in UV spectrophotometry is dependent solely on its
concentration, GUS procedures using HPLC-DAD detection
enable a semi-quantitative estimation of the drug concentra-
tion by dividing the peak area in the sample chromatogram
by the specific peak area, measured in 1 mg/mL of the ana-
lyte under the same conditions. The specific conditions and
recovery of the sample preparation need to be considered
using the corresponding correction factors.
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Figure 1 Example of an analytical strategy for the elucidation of an acute poisoning.
Enzym, enzymatic reaction; GC-MS, gas chromatography mass spectrometry; LC-MS, liquid chromatography mass spectrometry; IA, immu-
noassay; ionselect., ion selective electrode; CO-Hb, CO-hemoglobin; photometr., photometry; quant., quantitative; AAS, atomic absorption
spectrometry.
Whereas many compounds involved in intoxication can be
obtained commercially, others are difficult to acquire. In
these situations, the companies producing the compounds
can sometimes provide the laboratory with these standards
or commercial drug formulations (e.g., tablets) that can be
extracted. In the latter case, the concentrations determined
using these calibrators should only be considered to be semi-
quantitative as the purity of the standard is not known.
Identification of metals
Lithium
Lithium is a toxic metal and the severity of intoxication cor-
responds to its concentrations in serum. Quantification of
lithium with ion selective electrodes or flame emission pho-
tometry should be performed whenever the intake of this
drug is considered.
Iron
Poisoning with iron is rare and almost always involves chil-
dren who discover their mother’s pink iron supplements, and
then consume them like candy. The quantification of iron is
usually performed with use of colorimetric tests which are
available on clinical chemistry instruments.
Arsenic, mercury, thallium
Poisonings with arsenic are very rare in Europe, but are seen
more often in developing countries. There are still arsenic
containing herbicides and pesticides available, which then
may be used in suicide or homicide. In addition, acute intox-
ication with mercury is very rare, and is due to inhalation of
vapor or dust containing mercury. Thallium is easily
absorbed from the gastrointestinal tract and is distributed
throughout the body. In the blood compartment, thallium
can be found in erythrocytes. All of these metals are usually
analyzed using AAS or ICP-MS. ICP-MS allows for the
simultaneous measurement of multiple metal ions, which
makes the technique suitable for screening purposes. When
AAS or ICP-MS instruments are not available, cooperation
with an institution that regularly uses these techniques should
be established.
Identification of solvents and chemicals
Organic solvents
Besides the popular use of ethanol, the use of organic sol-
vents in intoxication has several reasons. Sometimes, a sol-
vent may be drunk mistakenly if it was stored in a beverage
bottle, or if self-produced liquors erroneously contain meth-
anol. Other times, organic solvents may be used as poisons
in suicide attempts. More recently, the abuse of solvents by
sniffing has become more popular, and may lead to intoxi-
cation. During the first phase after intake of solvents, these
compounds add to the osmolality, and their presence and the
amount taken can be estimated by calculating the osmolal
gap. The organic solvents most often detected in cases of
intoxication (methanol and ethylene glycol) are metabolized
to organic acids which do not contribute to the osmolality,
but do result in an increased anion gap.
The organic solvents can be determined by GC coupled to
different detectors (e.g., flame ionization or mass spectrom-
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etry) in specialized toxicological laboratories. The organic
acid metabolites can, for example, be quantified by ion
chromatography.
g-Hydroxybutyrate (GHB)
GHB is often used as a drug of abuse or as a date-rape drug.
It has a very short elimination half-life, which allows detec-
tion in serum or plasma for about 6 h, and in urine for about
12 h only. GHB usually is determined with a specific GC-
MS method after derivatization, such as silylation (30).
Cyanide
Cyanide is a very rare poison usually involved in cases of
suicide or homicide. Colorimetric tests enable fast and reli-
able quantification of cyanide in serum and urine. Colori-
metric, fluorimetric and chromatographic methods have been
described for the analyses of cyanide in biological fluids. A
simple and fast colorimetric method for the quantification of
cyanide in blood uses the reaction of cyanide with 1,2-dini-
trobenzene and 4-nitrobenzaldehyde in 2-methoxyethanol to
produce 2-nitrophenylhydroxylamine (31).
Conclusions
Laboratory diagnostics is essential in acute poisoning. Early
following admission to the hospital, general clinical chem-
istry and hematology tests should be performed to determine
the pathophysiological state of the patient. In addition, there
are many situations where the identification and sometimes
the quantification of the compound(s) involved are useful
and necessary. There are some situations where an antidote
can be started, such as intoxication with acetaminophen,
digoxin or amanitin. At other times, GUS procedures are
necessary when the anamnestic information does not provide
enough evidence that all compounds taken by the patient are
known. Independent of the analytical technique used (HPLC-
DAD, GC-MS and LC-MS), the limitations concerning
detection of the different compounds, the number of analytes
present in the library and the knowledge about the limitation
of the technique must be considered in the interpretation of
the results of a screening method. Usually, different methods
need to be used concomitantly in order to obtain reliable
results. Often, it is necessary not only to identify the poison,
but also to quantify its concentration in serum or plasma in
order to assure adequate treatment of the patient.
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